Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amendment: Patient Survival Rates in Myelodysplastic Syndrome Following Azacitidine Treatment

  • By

  • Kanticha Thammagul

  • Suppalux Limpiwattakee

  • Pichika Chantrathammachart

  • Teeraya Puavilai

  • Suporn Chuncharunee

  • Pimjai Niparuck

  • September 26, 2026

Share

  • 1

    The article is a correction to BMC Cancer 26, 699 (2026) regarding author name accuracy.

  • 2

    The original article contained an error in the author name Suppalux Limpiwattakee.

  • 3

    The erroneous name was listed as Suppalux Limpiwakee in the original publication.

  • 4

    The correction has been officially made to the original article.

  • 5

    The correction follows an update from the author group regarding the name error.

Original Source(s)

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

  • by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

  • September 26, 2026

Related Content

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

Deep learning-based segmentation of peritoneal cancer index regions from CT imaging

Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology